Updated results from two MD Anderson clinical trials presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting indicate improved outcomes for cancer patients with specific gene mutations when treated with targeted therapies. Targeted therapies from both the BEACON CRC and the BLC2001 clinical trials resulted in FDA approvals of treatments for subsets of patients with advanced colorectal and bladder cancers....
Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer...
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival of 44.4 months in adult and pediatric patients with advanced cancers and NTRK gene fusions, regardless of cancer type. In contrast, those with other mutations in NTRK that were not gene fusions saw only a 1% overall response rate of median overall survival of just 10.7 months, highlighting the...
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...